Trend
DailyUptrend (confirmed)
4 hourBullish
1 hourBullish
15 minBullish
5 minDescending Triangle
Daily trend turns down below $4.30
Key levels
Resistance$9.68
Resistance$9.05
Support$8.25
Support$7.54
Latest news & SEC filings
EarningsAtara Biotherapeutics reports third quarter 2026 financial results
DealAtara Biotherapeutics registers up to $200M in securities
SEC FilingAtara Biotherapeutics, Inc. filed a shelf registration for future offerings (Form S-3)
EarningsAtara Biotherapeutics posts smaller quarterly loss than expected
All ATRA news →Atara Biotherapeutics is a clinical-stage biotechnology company that develops off-the-shelf T-cell immunotherapies derived from Epstein-Barr virus-specific donor cells. Its lead therapy, tabelecleucel (Ebvallo), is authorized in Europe for a rare blood cancer that arises after organ or stem cell transplants, and is licensed to Pierre Fabre for commercialization globally. The company also has earlier-stage allogeneic CAR T programs aimed at cancers of the immune system's antibody-producing cells and autoimmune conditions. It operates in the United States and Europe.
Based on the company's 10-K filed Mar 16, 2026.
Nasdaq · Healthcare
SEPT Low Target
$13.00
SEPT Mid Target
$13.00
SEPT High Target
$13.00
Analyst Consensus
$13.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ATRA.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$13.00
15
Moat Score
NONE
4/9
Piotroski Score
-127.2
Altman Z-Score
Insider Signal
SELLING
1 buys / 11 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Cherry Brian N | director | Buy | 104,166 | $1000K | Sep 4, 2026 |
| Cherry Brian N | director | Buy | 24,000 | - | Jun 11, 2026 |
| HEIDEN WILLIAM K | director | Buy | 12,000 | - | Jun 9, 2026 |
| Fust Matthew K | director | Buy | 12,000 | - | Jun 9, 2026 |
| Ciongoli Gregory Austin | director 10% owner | Buy | 12,000 | - | Jun 9, 2026 |
| Nguyen AnhCo | director officer | Sale | 5,241 | $48K | May 18, 2026 |
| Grant-Huerta Yanina | officer | Sale | 2,414 | $22K | May 18, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
-6.3%
3yr Revenue CAGR
23.9%
EPS Growth YoY
122.52%
FCF Growth YoY
26.1%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for ATRA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:45:00 | $7.70 | 1,000 | $$8K | SELL |
| 15:00:03 | $7.84 | 2,928 | $$23K | BUY |
| 17:02:39 | $8.19 | 3,000 | $$25K | BUY |
| 19:44:02 | $8.00 | 1,120 | $$9K | SELL |
| 19:20:29 | $7.72 | 1,000 | $$8K | SELL |
5 dark pool trades shown · $$72K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ATRA. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
$ATRA filed a Form S-3 shelf registration statement on Tue Nov 10 covering up to $200 million in securities, including an at-the-market equity offering program of up to $23,011,805 in common stock thr...
Smart Money Moves $LITE — Wupen Yuen | Sale $430K $XOS — OSTERMANN DIETMAR | Sale $15K $ATRA — Cherry Brian N | Sale $1000K $KYMR — Adams Brian | Sale $140K $KYMR — Adams Brian | Sale $353K
Smart Money Moves $LITE — Wupen Yuen | Sale $430K $XOS — OSTERMANN DIETMAR | Sale $15K $ATRA — Cherry Brian N | Sale $1000K $KYMR — Adams Brian | Sale $140K $KYMR — Adams Brian | Sale $353K
Join 3,500+ traders discussing ATRA in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
SEPT's Trading AI has generated a free, downloadable PDF research report for Atara Biotherapeutics, Inc. (ATRA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Atara Biotherapeutics, Inc. (ATRA) is at $8.28, up 0.55% (+$0.04) at the Nov 12, 2026 close.
Latest ATRA news — Nov 11, 2026: Atara Biotherapeutics reports third quarter 2026 financial results · Nov 10, 2026: Atara Biotherapeutics registers up to $200M in securities
The average analyst price target for ATRA is $13.00, ranging from $13 to $13, based on 1 analysts. Latest: Canaccord Genuity upgrade on May 8, 2026.
Analyst ratings for ATRA: 1 Buy, 0 Hold, 0 Sell — consensus Buy.
ATRA last reported on Aug 12, 2026: EPS -$0.32 vs -$0.32 expected — a miss of 1.6%.
ATRA does not currently pay a dividend.
Support: $8.25, $7.54, $6.80. Resistance: $9.05, $9.68, $10.50.
Insider activity: SELLING, 1 buys and 11 sells in the last 90 days.
Nov 11, 2026: Atara Biotherapeutics reports third quarter 2026 financial results · Nov 10, 2026: Atara Biotherapeutics registers up to $200M in securities · Nov 10, 2026: Atara Biotherapeutics, Inc. filed a shelf registration for future offerings (Form S-3)